Patents by Inventor Rekha Bansal

Rekha Bansal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
    Publication number: 20160333079
    Abstract: An aglycosylated humanized anti-C3b (AAC3b) antibody or antigen binding fragment thereof includes a modification at a conserved N-linked site in the CH2 domains of an Fc portion of the antibody or antigen binding fragment thereof.
    Type: Application
    Filed: February 1, 2016
    Publication date: November 17, 2016
    Inventor: Rekha Bansal
  • AGLYCOSYLATED ANTI-Bb ANTIBODIES AND USES THEREOF
    Publication number: 20160333080
    Abstract: An aglycosylated humanized anti-Bb (AAfBb) antibody or antigen binding fragment thereof includes a modification at a conserved N-linked site in the CH2 domains of an Fc portion of the antibody or antigen binding fragment thereof.
    Type: Application
    Filed: February 2, 2016
    Publication date: November 17, 2016
    Inventor: Rekha Bansal
  • COMPOSITIONS AND METHODS OF TREATING OCULAR DISEASES
    Publication number: 20160319002
    Abstract: A method of treating a complement mediated ocular inflammation, hemorrhaging and fibrosis, and the pathological consequences thereof, in a subject in need thereof, the method comprising of administering to the subject a therapeutically effective amount of an antibody which inhibits the alternative complement pathway, wherein the antibody administered is effective for inhibiting complement mediated ocular inflammation, hemorrhaging and fibrosis, and the pathological consequences thereof.
    Type: Application
    Filed: August 6, 2014
    Publication date: November 3, 2016
    Inventor: Rekha Bansal
  • METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH HUMAN ANTI-FACTOR C3 ANTIBODIES AND USES THEREOF
    Publication number: 20160244513
    Abstract: A method of inhibiting complement activation mediated by C3b inhibitors in a subject includes administering a C3B inhibitor to the subject to inhibit at least one of C3b binding to factors B and properdin, inhibit C3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of C3a, C5a, and MAC.
    Type: Application
    Filed: November 23, 2015
    Publication date: August 25, 2016
    Inventor: Rekha Bansal
  • ALTERNATIVE PATHWAY SPECIFIC ANTIBODIES FOR TREATING ARTHRITIS
    Publication number: 20160207987
    Abstract: A method of selecting a genus of therapeutic antibodies includes selecting antibodies with the following criteria; a) do inhibit cell lysis under conditions wherein the alternative pathway is isolated from the classical pathway; and b) do not inhibit cell lysis under conditions wherein the classical pathway is isolated from the alternative pathway; and c) do not inhibit cell lysis under conditions wherein the classical pathway and alternative pathway are active; and d) do inhibit C3b produced exclusively by the alternative pathway;
    Type: Application
    Filed: September 23, 2015
    Publication date: July 21, 2016
    Inventor: Rekha BANSAL
  • ALTERNATIVE PATHWAY SPECIFIC ANTIBODIES FOR TREATING HEMOLYTIC DISEASES
    Publication number: 20160122419
    Abstract: A method of treating a hemolytic disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of an antibody that binds to a component of alternative pathway C3 convertase and selectively inhibits C3a, C5a, C3b, C5b, and C5b-9 produced exclusively by the alternative pathway, without inhibiting any of the classical pathway's ability to produce C3a, C5a, C3b, C5b, and C5b-9.
    Type: Application
    Filed: October 4, 2013
    Publication date: May 5, 2016
    Inventor: Rekha BANSAL
  • Humanized and chimeric anti-factor Bb antibodies and uses thereof
    Patent number: 9243070
    Abstract: A method of inhibiting complement activation mediated by Bb inhibitors in a subject includes administering a Bb inhibitor to the subject to inhibit at least one of Bb binding to factors B and properdin, inhibit C3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of C3a, C5a, and MAC.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: January 26, 2016
    Assignee: Novelmed Therapeutics, Inc.
    Inventor: Rekha Bansal
  • Humanized anti-factor C3b antibodies and uses thereof
    Patent number: 9243060
    Abstract: A method of inhibiting complement activation mediated by C3b inhibitors in a subject includes administering a C3b inhibitor to the subject to inhibit at least one of C3b binding to factors B and properdin, inhibit C3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of C3a, C5a, and MAC.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: January 26, 2016
    Assignee: Novelmed Therapeutics, Inc.
    Inventor: Rekha Bansal
  • METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Bb SPECIFIC ANTIBODIES AND USE THEREOF
    Publication number: 20160002348
    Abstract: A pharmaceutical composition includes an isolated anti-Bb antibody or antigen binding portion thereof produced by a hybridoma cell line deposited under ATCC Accession Number PTA-8543 or an isolated anti-Bb antibody or antigen binding portion thereof that competitively inhibits binding of the antibody or antigen binding portion produced by the hybridoma cell line deposited under ATCC Accession Number PTA-8543 to the Bb segment of factor B; and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: March 16, 2015
    Publication date: January 7, 2016
    Inventor: Rekha Bansal
  • ALTERNATIVE PATHWAY SPECIFIC ANTIBODIES FOR TREATING HEMOLYTIC DISEASES
    Publication number: 20150315268
    Abstract: A method of treating a hemolytic disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of an antibody that binds to a component of alternative pathway C3 convertase and selectively inhibits C3a, C5a, C3b, C5b, and C5b-9 produced exclusively by the alternative pathway, without inhibiting any of the classical pathway's ability to produce C3a, C5a, C3b, C5b, and C5b-9.
    Type: Application
    Filed: April 6, 2015
    Publication date: November 5, 2015
    Inventor: Rekha Bansal
  • AGLYCOSYLATED HUMAN ANTIBODY AND FUSION PROTEIN AND USES THEREOF
    Publication number: 20150291686
    Abstract: The invention is a method for reducing the effector functions of a therapeutic neutralizing antibody by administering to the afflicted subject an effective amount of an engineered aglycosylated human monoclonal antibody containing an engineered Fc region, wherein aglycosylation of the Fc region prevents therapeutic antibody-mediated cell activation, inflammation, Clq binding to the antibody and antibody triggered classical pathway activation.
    Type: Application
    Filed: December 28, 2012
    Publication date: October 15, 2015
    Inventor: Rekha Bansal
  • METHOD FOR TREATING INFLAMMATORY CONDITIONS
    Publication number: 20150216876
    Abstract: A method for treating an autoimmune disease in a subject includes administering to the subject a therapeutically effective amount of an agent comprising an imidazole, an estrogen receptor agonist, or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 13, 2015
    Publication date: August 6, 2015
    Inventor: Rekha Bansal
  • Method for treating inflammatory conditions
    Patent number: 9040507
    Abstract: A method for treating an autoimmune disease in a subject includes administering to the subject a therapeutically effective amount of an agent comprising an imidazole, an estrogen receptor agonist, or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: May 26, 2015
    Assignee: Novelmed Therapeutics, Inc.
    Inventor: Rekha Bansal
  • NEO ANTIBODIES FOR DIAGNOSTIC IMAGING OF TISSUE INJURY
    Publication number: 20150139899
    Abstract: A method for diagnosing the development of a tissue injury in a subject comprising administering a sample of neoantibodies to the subject's tissue for the purpose of detecting the presence of neoepitopes bearing complement proteins.
    Type: Application
    Filed: January 26, 2015
    Publication date: May 21, 2015
    Inventor: Rekha Bansal
  • Methods and compositions of inhibiting complement and cellular activation with Dextran Sulfate
    Patent number: 9023831
    Abstract: A method of inhibiting the adverse effects of complement pathway, activation products in a subject comprising administering to the subject an amount of Dextran Sulfate effective to inhibit formation of alternative complement pathway activation product.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: May 5, 2015
    Assignee: Novelmed Therapeutics, Inc.
    Inventor: Rekha Bansal
  • HUMANIZED AND CHIMERIC ANTI-FACTOR BB ANTIBODIES AND USES THEREOF
    Publication number: 20150093390
    Abstract: A method of inhibiting complement activation mediated by Bb inhibitors in a subject includes administering a Bb inhibitor to the subject to inhibit at least one of Bb binding to factors B and properdin, inhibit C3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of C3a, C5a, and MAC.
    Type: Application
    Filed: April 2, 2013
    Publication date: April 2, 2015
    Inventor: Rekha Bansal
  • Method of inhibiting complement activation with factor Bb specific antibodies
    Patent number: 8981060
    Abstract: A process of inhibiting the adverse effects of alternative complement pathway activation products in a subject includes administering to the subject an amount of anti-factor Bb antibody effective to selectively inhibit formation of an alternative complement pathway activation products C3a, C5a, and C5b-9, and activation of neutrophils, monocytes, and platelets.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: March 17, 2015
    Assignee: Novelmed Therapuetics, Inc.
    Inventor: Rekha Bansal
  • HUMANIZED AND CHIMERIC ANTI-FACTOR C3 ANTIBODIES AND USES THEREOF
    Publication number: 20150064202
    Abstract: A method of inhibiting complement activation mediated by C3b inhibitors in a subject includes administering a C3b inhibitor to the subject to inhibit at least one of C3b binding to factors B and properdin, inhibit C3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of C3a, C5a, and MAC.
    Type: Application
    Filed: April 2, 2013
    Publication date: March 5, 2015
    Applicant: NovelMed Therapeutics, Inc.
    Inventor: Rekha Bansal
  • Neoantibodies for diagnosing tissue injury
    Patent number: 8940490
    Abstract: A method for diagnosing the development of a tissue injury in a subject comprising administering a sample of neoantibodies to the subject's tissue for the purpose of detecting the presence of neoepitopes bearing complement proteins.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: January 27, 2015
    Assignee: Novelmed Therapeutics, Inc.
    Inventor: Rekha Bansal
  • ANTI-PROPERDIN ANTIBODIES
    Publication number: 20140328846
    Abstract: A method of inhibiting alternative complement pathway activation in a mammal includes administering an amount of an antibody and/or fragment thereof that specifically binds to an epitope of the N terminus end of properdin effective to the inhibit alternative complement pathway in the subject.
    Type: Application
    Filed: June 11, 2014
    Publication date: November 6, 2014
    Inventor: Rekha Bansal